SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000899243-21-002081
Filing Date
2021-01-14
Accepted
2021-01-14 17:54:00
Documents
1
Period of Report
2021-01-12

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 23878
  Complete submission text file 0000899243-21-002081.txt   27103
Mailing Address 450 KENDALL STREET CAMBRIDGE MA 02142
Business Address 450 KENDALL STREET CAMBRIDGE MA 02142 6174259200
MPM Oncology Impact Management LP (Reporting) CIK: 0001687078 (see all company filings)

State of Incorp.: DE | Fiscal Year End: 1231
Type: 4 | Act: 34 | File No.: 001-39856 | Film No.: 21529931

Mailing Address 450 KENDALL STREET CAMBRIDGE MA 02142
Business Address 450 KENDALL STREET CAMBRIDGE MA 02142 617-425-9200
UBS Oncology Impact Fund L.P. (Reporting) CIK: 0001691428 (see all company filings)

State of Incorp.: E9 | Fiscal Year End: 1231
Type: 4 | Act: 34 | File No.: 001-39856 | Film No.: 21529928

Mailing Address 450 KENDALL STREET CAMBRIDGE MA 02142
Business Address 450 KENDALL STREET CAMBRIDGE MA 02142 6174259200
MPM Oncology Impact Management GP LLC (Reporting) CIK: 0001721035 (see all company filings)

State of Incorp.: DE | Fiscal Year End: 1231
Type: 4 | Act: 34 | File No.: 001-39856 | Film No.: 21529930

Mailing Address 450 KENDALL STREET CAMBRIDGE MA 02142
Business Address 450 KENDALL STREET CAMBRIDGE MA 02142 6174259200
Oncology Impact Fund (Cayman) Management L.P. (Reporting) CIK: 0001721036 (see all company filings)

State of Incorp.: E9 | Fiscal Year End: 1231
Type: 4 | Act: 34 | File No.: 001-39856 | Film No.: 21529929

Mailing Address ONE MAIN STREET SUITE 520 CAMBRIDGE MA 02142
Business Address ONE MAIN STREET SUITE 520 CAMBRIDGE MA 02142 617-410-4650
Cullinan Management, Inc. (Issuer) CIK: 0001789972 (see all company filings)

IRS No.: 813867811 | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
Office of Life Sciences